Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,766
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Tesla: Shares fall as deliveries come in below consensus
stocks
Will Australia’s dwindling fuel supplies impact this share?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.20 | 4.30 | -0.05% |
| CAC 40 | 7,942.49 | 19.90 | -0.25% |
| DAX 40 | 22,980.95 | 187.13 | -0.81% |
| Dow JONES (US) | 46,354.47 | 315.41 | -0.68% |
| FTSE 100 | 10,373.98 | 62.31 | -0.60% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,819.38 | 176.96 | -0.80% |
| Nikkei 225 | 53,429.56 | 15.88 | 0.03% |
| NZX 50 Index | 13,069.66 | 167.51 | 1.30% |
| S&P 500 | 6,569.44 | 42.39 | -0.64% |
| S&P/ASX 200 | 8,728.80 | 1.50 | -0.02% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |